{"id":"NCT01135992","sponsor":"Novo Nordisk A/S","briefTitle":"Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)","officialTitle":"A Trial Assessing the Implications of Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™: SIMPLIFY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2010-06-03","resultsPosted":"2016-01-22","lastUpdate":"2016-01-22"},"enrollment":143,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IGlar/IDeg","type":"EXPERIMENTAL"},{"label":"IDeg 3TW","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes mellitus.","primaryOutcome":{"measure":"HbA1c (Glycosylated Haemoglobin)","timeFrame":"Week 4 and Week 16","effectByArm":[{"arm":"IGlar/IDeg","deltaMin":7.4,"sd":1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":142},"commonTop":[]}}